Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.08

+0.9%

Dec 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	5/17/2006 10:29:55 PM
	Read Replies (2) of 52153

This doesn't sound as if it's likely to be good news... 02:32 ET Pharmion and GPC Biotech announce independent data monitoring board recommendation (PHRM) 18.00 -0.42:Co and GPC Biotech (GPCB) announce that the independent Data Monitoring Board for the satraplatin Phase 3 registrational trial, Satraplatin and Prednisone Against Refractory Cancer has notified the cos that it wishes to conduct an expedited interim analysis of overall survival data from the SPARC trial. The cos have agreed to this request and the D.M.B. is expected to meet to discuss the data prior to the end of the second quarter of 2006. The cos have not had access to the data that caused the D.M.B. to request this expedited review of overall survival, however in its April 25th meeting, the D.M.B. also had access to preliminary overall survival data. The cos are now and will continue to remain blinded to the data during this review process. 03:08 ET Spectrum Pharma: Independent data monitoring board recommends expedited interim analysis of overall survival data for Satraplatin Phase 3 trial (SPPI) 4.29 +0.39:Co announces that its satraplatin co-development partner, GPC Biotech (GPCB), was notified by the independent Data Monitoring Board for the satraplatin Phase 3 registrational trial, Satraplatin and Prednisone Against Refractory Cancer that it wishes to conduct an expedited interim analysis of overall survival data from the SPARC trial. The co has agreed to this request and the D.M.B. is expected to meet to discuss the data prior to the end of the second quarter of 2006.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next